Dr. Zohar's Research
Oncology Netwrok Co-Founder, Dr. Zohan Etzioni, is a Senior Postdoctoral Researcher at the Ludwig Cancer Research Institute from Oxford University.
Last updated
Oncology Netwrok Co-Founder, Dr. Zohan Etzioni, is a Senior Postdoctoral Researcher at the Ludwig Cancer Research Institute from Oxford University.
Last updated
Dr. Zohar Etzioni’s current research is at the cutting edge of cancer detection and treatment, integrating computational, genomic, and machine learning methodologies to advance the field. His primary focus lies in leveraging somatic mutations and DNA methylation patterns to revolutionize early cancer detection and therapeutic monitoring.
You can read our full feature blog here:
By analyzing cell-free DNA (cfDNA) through liquid biopsy techniques, he is addressing critical challenges in oncology, such as non-invasive diagnostics, minimal residual disease (MRD) detection, and personalized treatment strategies.
At the Ludwig Cancer Research Center, Dr. Etzioni leads pioneering efforts to transform how cancer is detected and monitored. His research focuses on harnessing somatic mutations and DNA methylation patterns to advance early cancer diagnostics and therapeutic monitoring. By leveraging liquid biopsy techniques, Dr. Etzioni has unlocked new possibilities in non-invasive diagnostics, enabling the identification of circulating tumor DNA (ctDNA) from blood samples.
One of his standout contributions is the application of TET-assisted pyridine borane sequencing (TAPS), an advanced technique for DNA methylation analysis. This approach allows for ultra-sensitive detection of epigenetic changes, paving the way for diagnosing cancer at its earliest stages. Beyond diagnostics, Dr. Etzioni’s work in minimal residual disease (MRD) monitoring has shown remarkable promise in identifying as few as one cancer cell among a million healthy ones, offering hope for personalized treatment strategies.
Dr. Etzioni’s integration of artificial intelligence (AI) and machine learning further exemplifies his forward-thinking approach. By decoding complex genomic datasets, his work has led to the discovery of novel biomarkers, offering insights into how patients might respond to emerging therapies like immunotherapy.
